Updates

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 E: co.secretary@biocon.com www.biocon.com BIO/SECL/TG/2026-27/75 October 26, 2026 To To The Manager, The Manager, BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate Communication Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai – 400 001 Mumbai – 400 051 Scrip Code - 532523 Scrip Symbol - BIOCON Subject: Company Statement Dear Sir/Madam, Please find enclosed Company Statement w.r.t. “Biocon Secures Market Entry for Yesintek™, a Proposed Biosimilar to Stelara®, in Additional Global Markets”. The above information will also be available on the website of the Company at www.biocon.com. Kindly take the same on record and acknowledge. Thanking You, Yours faithfully, For Biocon Limited Rajesh U. Shanoy Company Secretary and Compliance Officer M. No.: ACS 16328 Encl: Company Statement NOTIFICATION TO STOCK EXCHANGE COMPANY STATEMENT Biocon Secures Market Entry for Yesintek™, a Proposed Biosimilar to Stelara®, in Additional Global Markets Bengaluru, Karnataka, India, October 26, 2026 Biocon Limited (BSE code: 532523, NSE: BIOCON) has signed a license agreement with Janssen Sciences Ireland clearing the way for the commercialization of Yesintek™, its proposed biosimilar to Stelara® (Ustekinumab), in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan with immediate effect. This milestone builds on the Company’s previously announced agreements with Janssen that secured market entry dates for Yesintek™ in the United States, and in Europe, the UK, Canada and Japan. These additional market entry rights for biosimilar Ustekinumab will allow Biocon to offer an affordable and effective treatment option for patients impacted by autoimmune diseases in these markets. Yesintek™ is a human interleukin-12 and -23 antagonist that disrupts IL-12 and IL-23 mediated signalling in immune mediated diseases and has been approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. The reference brand, Stelara®, had worldwide sales of $6.08 billion in 2025^. ^Johnson & Johnson Reported 2025 Sales Note: • All trademarks, registered or unregistered, are the property of their respective owners. • Product launches in all the countries / regions are subject to regulatory approval. Forward-Looking Statement: Statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update these statements except as required by law.